Loading...
Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
ABT‐751 is an orally bioavailable sulfonamide with antimitotic properties. A nonrandomized phase 1 dose‐escalation study of ABT‐751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose‐limiting toxicity (DLT), and pharmacok...
Na minha lista:
| Udgivet i: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4892995/ https://ncbi.nlm.nih.gov/pubmed/26632033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.681 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|